- Addition of pelvic external beam radiotherapy (EBRT) to adjuvant chemotherapy yields a modest survival benefit in patients with stage III-IVA endometrial cancer.
- OS benefit was significant in patients with stage IIIC2 endometrioid and IIIB-C nonendometrioid disease.
Why this matters
- These findings suggest heterogeneity in these patients and may help identify those most likely to benefit from combined modality treatment.
- 13,270 patients with FIGO stages III-IVA endometrial carcinoma received total hysterectomy and adjuvant chemotherapy during 2004-2016.
- Funding: None disclosed.
- Median follow-up, 3.7 years.
- 43% of patients received pelvic EBRT.
- Patients with endometrioid disease: EBRT+chemotherapy showed OS advantage vs chemotherapy alone in univariate (77% vs 72%; P<.0001 and multivariate p=".003)" analysis. style="list-style-type:circle;">
- OS significantly improved in stage IIIC2 disease (HR, 0.73; P=.01).
- The benefit of EBRT persisted in patients with >15 lymph nodes removed (aHR, 0.65; P=.01) or ≥5 para-aortic nodes removed (aHR, 0.56; P=.002).
- Observational study.